DESLOR 5/MG FC TAB 20/FC TAB

Indications

Approved Uses

Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Dosage & Administration

Dosing by Condition

Allergic rhinitis (adults and adolescents ≥12 years): 5 mg once daily. Chronic idiopathic urticaria (adults and adolescents ≥12 years): 5 mg once daily

Initial Dose

5 mg once daily.

Maintenance Dose

5 mg once daily.

Maximum Dose

5 mg once daily.

Children's Dosage

Not indicated for children under 12 years with this formulation; use oral solution for pediatrics.

Dose Adjustment Notes

In renal impairment and/or hepatic impairment: consider an initial dose of 5 mg every other day in adults (and age-appropriate reduced frequency in pediatrics).

How to Take

Swallow the film‑coated tablet whole with water; may be taken with or without food; take once daily (preferably at the same time each day).

Safety & Warnings

Contraindications

Hypersensitivity to desloratadine or loratadine, hypersensitivity to any excipient in the formulation

Warnings & Precautions

Use caution and consider dose adjustment in severe renal or hepatic impairment; use caution in patients with a history of seizures; discontinue and seek care if hypersensitivity occurs.

Age Restriction

For this 5 mg film‑coated tablet: use in adults and adolescents ≥12 years; younger children should use age-appropriate pediatric formulations (e.g., oral solution).

Driving Warning

Does not cause drowsiness

Drug Interactions

Drug Interactions

Ketoconazole, erythromycin, azithromycin, fluoxetine, and cimetidine can increase desloratadine exposure; interactions are usually not clinically significant (including QT risk) at recommended doses.

Interaction Severity

Clinically significant interactions are uncommon; moderate PK increases have been reported with ketoconazole and erythromycin (and sometimes cimetidine/fluoxetine), generally without meaningful clinical effect; MAOI-related ‘serious’ anticholinergic interaction is not applicable to desloratadine.

Food Interaction

No restriction.

Special Populations

Children

Not indicated for children under 12 years with this formulation; use oral solution for pediatrics.

Kidney Impairment

Severe renal impairment: 5 mg every other day (adults/adolescents using the 5 mg tablet).

Liver Impairment

Severe hepatic impairment: 5 mg every other day (adults/adolescents using the 5 mg tablet).

Storage & Patient Advice

Stopping the Medicine

Safe to stop anytime.

Overdose

Seek urgent medical advice/poison center; expected symptoms include somnolence, tachycardia, and headache; management is symptomatic/supportive (consider decontamination if early) and desloratadine is not removed by hemodialysis.

Patient Counseling

Take 1 tablet (5 mg) once daily with or without food; do not exceed 1 tablet/day. May cause drowsiness in some-use caution with driving until you know your response; avoid alcohol if it worsens sedation. Ask a clinician before use if you have kidney or liver disease. Store below 30°C in the blister, protected from heat/moisture.

Pharmacology

Mechanism of Action

Selective peripheral histamine H1‑receptor antagonist that reduces histamine‑mediated allergic symptoms with minimal anticholinergic and minimal CNS effects at recommended doses.

Bioavailability

Oral absolute bioavailability is not well established/commonly reported as a single definitive percentage; exposure is dose‑proportional and not meaningfully affected by food.

Product Information

Available Dosage Forms

For DESLOR (Jamjoom) specifically: film‑coated tablet; other desloratadine products may also be available as oral solution/syrup (and in some markets ODT), but ODT is not supported by the verified product data for this item.

Composition per Dose

Each film-coated tablet: 5 mg desloratadine

Generic Availability

Yes

OTC Alternatives

Other OTC second‑generation antihistamines: loratadine, cetirizine (or levocetirizine where OTC), and fexofenadine.

Symptom Target

Allergy, Runny Nose

Sedating

No

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 14-08-2026